Articles tagged with Mtor Pathway
Researchers discovered that neuronal nitric oxide synthase drives neuroblastoma through the mTOR signaling cascade. Treating cancer cells with a selective inhibitor called BA-101 collapsed tumor growth in mice with striking force, and silencing the nNOS gene also led to significant results.
Two Russian scientists' conceptual similarities challenge conventional aging views. Their ideas about hyperfunction and elevation remain relevant to modern research. Golubev explores the historical connections between Dilman and Blagosklonny, highlighting their contributions to aging science.
A new study found no clear clinical evidence that rapamycin can extend healthspan or delay aging in healthy adults, despite promising results in animal studies. The review suggests that off-label use of rapamycin should be approached with caution due to limited evidence and potential side effects.
Dr. Blagosklonny's work introduced a new theory and promoted the use of rapamycin to slow aging and extend healthy life by targeting the mTOR pathway, leading to improved immune responses, heart protection, and potential cancer prevention.
A new study reveals that delta opioid receptor agonist KNT-127 has a rapid and effective antidepressant effect with minimal side effects. The research highlights the molecular mechanisms underlying its action, including mTOR signaling pathways and Akt activation in the medial prefrontal cortex.
Researchers discovered that tumor dormancy in breast cancer can be triggered by specific signaling changes within small cell clusters, called tumor emboli. Key mechanisms include reduced activity of mTOR and structural shifts in E-cadherin, which are regulated by the PI3K pathway.
Researchers identified a molecular mechanism that controls embryonic diapause in humans, allowing cells to temporarily slow down development. This dormant state is characterized by reduced cell division and slower development, and can be reversed when the mTOR pathway is reactivated.
A research team from Osaka University identified a key osteoporosis-related gene, Men1, and developed a new animal model of the disease. The study found that inactivation of Men1 led to cellular senescence in osteoblasts, reducing bone formation activity and increasing bone resorption.
In animal models, increasing mTOR activity just slightly accelerates aging and shortens lifetime by up to 20%. This research provides clues on why obesity-related diseases worsen with age. A new model allows researchers to study the relationship between nutrient increase and organ aging.
Researchers at Ben-Gurion University have discovered a molecular mechanism that enables cancer cells to survive under glucose starvation. By targeting this pathway, they aim to develop a molecule that can block the survival of tumor cells while leaving healthy cells unaffected.
Researchers found a significant association between neighborhood deprivation and DNA methylation in brain tissue, which may be linked to immune response. The study identified one CpG site (cg26514961, PLXNC1 gene) significantly associated with neighborhood deprivation after controlling for covariates.
Research at the University of Gothenburg reveals a link between maternal protein intake during pregnancy and the formation of facial bone structures in offspring. The study found that a particular signaling pathway, mTOR, plays a crucial role in shaping the face.
Research reveals that FoxO6 upregulates ApoC3, leading to increased lipid accumulation and liver damage in aged rats on a high-fat diet. The study suggests that targeting this pathway may offer therapeutic strategies against hepatic steatosis.
Researchers have discovered that PR55α, a regulatory subunit of PP2A phosphatase, inhibits p16 expression and blocks cellular senescence induction by γ-irradiation. This finding provides a new insight into the regulation of the p16/RB pathway in response to stressors.
Researchers identified a new PD-1 immune checkpoint mechanism promoting merkel cell carcinoma growth. MCC cells express PD-1 and its receptor binding accelerates tumor growth via mTOR pathway activation.
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
Researchers propose disease-oriented dosing of rapamycin to delay age-related diseases and increase lifespan. By decelerating early development of these diseases, rapamycin may help individuals live longer.
Researchers found that GPR141 enhances cell migration and proliferation in breast cancer by activating the p-mTOR/p53 signaling pathway. Silencing GPR141 restores p53 expression and attenuates tumor growth, suggesting its role in regulating breast cancer progression and metastasis.
Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.
Researchers explore cellular senescence's complex relationship with growth stimulation and cell cycle arrest, revealing potential anti-aging drug targets. Understanding these mechanisms is crucial for developing new treatments for age-related diseases.
Researchers investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. Everolimus treatment significantly inhibited cell growth and reduced tumor angiogenesis and lymphangiogenesis.
Researchers from Johns Hopkins Medicine have identified a novel mechanism of tumor formation in kidney cancers, highlighting the role of overactive mTORC1 signaling pathway and loss of the TSC tumor suppressor gene. Activation of microphthalmia transcription factors (MITF) family by unopposed mTOR signaling may lead to abnormal cell gr...
A new study suggests that prelamin A, a precursor of lamin A, accumulates with age and may drive normal aging. Researchers propose this protein as a target for intervention strategies to extend healthspan and lifespan.
A team from the University of Geneva has identified the structure of the SEA complex, a key regulator of cell growth, and how it controls the activity of the major regulator of cell growth, mTOR. The discovery provides new insights into how cells perceive nutrient levels to regulate their growth.
Researchers discovered a gene mutation that causes faulty RNA processing in worms, leading to increased longevity. The PUF60 gene affects the mTOR signalling pathway, which regulates cell metabolism and has been a target for anti-aging drugs.
Researchers found that ruxolitinib, a clinically approved drug, suppresses ICB-resistant melanomas by reprogramming TILs and relying on host TNF signaling. This discovery offers a potential target for bypassing therapeutic resistance in advanced melanoma patients.
Researchers found that mTOR inhibition is crucial for p53-mediated tumor suppression, delaying cancer and increasing lifespan. In the absence of mTOR inhibition, cancer-promoting senescent cells drive tumor growth.
A new study published in Cell Reports has identified the molecular pathways responsible for reduced seizures during fasting. The researchers found that amino acid sensing plays a critical role in the beneficial effects of fasting on seizures, suggesting targeted dietary strategies may be effective for patients without DEPDC5 mutations.
A study published in Cell Stem Cell found that mitochondrial dynamics regulate the dormant state of adult muscle stem cells, which are essential for tissue stability. The researchers discovered that the protein OPA1 regulates this process and its depletion leads to severe muscle stem cell defects.
A study by CNIC scientists has identified a key role for the MKK3/6–p38γ/δ signaling pathway in cardiac hypertrophy. Inhibition of p38α promotes an unexpected activation of the other branch of the pathway, consisting of the proteins MKK3, p38γ, and p38δ. This activation induces another key pathway in cardiac hypertrophy, the mTOR pathway.
Researchers at UT Health San Antonio found that rapamycin causes an increase in beta-amyloid protein plaques in mouse models, contradicting its potential benefits. However, a novel method to decrease plaques was discovered by deleting the Tsc1 gene from microglia, leading to increased Trem2 levels and decreased plaques.
The article proposes a new framework for understanding the hallmarks of cancer and aging, highlighting their shared underlying principles. Dr. Blagosklonny's hyperfunction theory arranges these hallmarks in a hierarchical structure, revealing common signaling pathways involved in both aging and cancer.
Researchers found that blocking an overactive signaling pathway during the first five weeks of life prevents autism symptoms from developing in mice. The study suggests that targeting this critical period could lead to a potential cure for autism.
A Canadian research team has identified a critical period in postnatal brain development that contributes to neurodevelopmental disorders associated with tuberous sclerosis. The study suggests that a mutation in the TSC1 gene disrupts the mTOR signaling pathway, leading to abnormal cell proliferation and synaptic connections defects.
A recent study by the CNIO reveals that rapamycin can worsen diseases associated with short telomeres, but may be beneficial in other cases. The researchers found that mice with short telomeres are more sensitive to nutrients and hyper-activated mTOR pathway.
Follicular lymphoma originates from mutations in RagC gene on mTOR signalling pathway, affecting B cell growth. Rapamycin treatment delays progression and prolongs survival in mice with RagC mutations.
Exercise induces improved motor skills through activation of the mechanistic target of rapamycin (mTOR) pathway, which stimulates spinogenesis and neural plasticity. The study provides direct evidence that exercise-activated mTOR is necessary for enhanced cognitive functions.
Researchers characterized mEAK-7, a human equivalent of EAK-7, which regulates cell growth and development. The study found that mEAK-7 activates an alternative pathway in cells, potentially controlling disease progression. Disrupting this process could lead to new therapies for cancer and other diseases.
Researchers discovered that a specific neural signal in the brain regulates young animals' ability to learn behavioral patterns from adults, particularly in zebra finches. The findings suggest that disruptions in this protein complex may be involved in neurodevelopmental disorders, such as autism spectrum disorder.
Researchers expose newborn mice to isoflurane, a widely used anesthetic agent, and find chronic activation of the mTOR pathway, which affects normal brain development. The study reveals abnormal neuron structure and impaired learning abilities in mice exposed to isoflurane.
Researchers have identified potential therapies for myotonic dystrophy type I (MD1) by targeting AMPK and mTORC1 pathways, which are disrupted in MD1 muscle tissue. Treatment with drugs that activate these pathways improves muscle function and reduces abnormal gene splicing.
Researchers at the University of Pennsylvania School of Medicine have discovered a molecular trigger that can activate a 'browning program' in white adipocytes, making them more like energy-burning brown adipocytes. This discovery could lead to new treatments for obesity and diabetes.
A Clemson University scientist is studying how alterations in a complex brain pathway cause neurological disorders like autism and epilepsy. The researcher aims to determine the role of amino acid transporters in brain development.
A recent study reveals a novel crosstalk mechanism between mitochondrial translation and cytoplasmic translation, essential for spermatogenesis. The mTOR signaling pathway helps balance the dynamic between mitochondrial translation and cytoplasmic translation, preventing negative impacts on protein quality and half-life.
Pediatric researchers identified a new syndrome causing intellectual disability, linked to a mutation in the TBCK gene. A potential targeted treatment using an amino acid supplement has been proposed based on cell studies.
Scientists discover that activating mTOR pathway plays a critical role in beiging of white fat cells to fight diabetes. Rapamycin, a drug previously used as an immunosuppressant, is found to induce beige fat cell formation and improve glucose metabolism.
Researchers at Hong Kong University of Science and Technology found that enhancing neuronal activity through melanopsin and DREADD-Gq stimulates axonal regeneration in adult mice. This suggests a new approach to facilitate neural repair after CNS damage.
Researchers at Johns Hopkins Medicine found that the mammalian target of rapamycin (mTOR) pathway is active in many difficult-to-treat pediatric brain tumors, offering a potential new target for treatment. Blocking this pathway with an experimental drug reduced tumor growth by up to 73% in laboratory studies.
The study found that mutant RBS cells exhibited aberrant ribosome malfunction, leading to upregulation of p53 protein and strong inhibition of mTOR signaling. Supplementing L-leucine partially rescued defects in both human skin cells and zebrafish embryos carrying the mutated ESCO2 gene.
Researchers found that mTORC1 serves as a rheostat to control regulatory T cells, which suppress the immune system's inflammatory response. The study challenges prior understanding of the mTOR pathway's role in regulating specialized T cells.
Researchers have discovered how and why an anti-cancer therapy stops working when tumor cells become starved of oxygen. This new understanding could lead to the development of more effective therapies for cancer treatment.
Researchers discovered a molecular mechanism that makes glioblastoma resistant to mTOR inhibitors, leading to the development of a new treatment approach. The novel combination therapy combines an mTOR inhibitor with low-dose arsenic to reverse resistance and induce tumor cell death.
A new study reveals that mTOR plays a key role in the complex signaling process that helps cells know when to grow and when to sit tight. The research found that mTOR turns itself on in a positive feedback loop involving the destruction of DEPTOR, a protein that normally holds it off.
A novel mouse model has identified a molecular signaling pathway underlying preterm labor, which may lead to new strategies for combating the major global health issue in humans. The study suggests that inhibiting mTORC1 signaling with rapamycin could prevent premature aging and birth.
Researchers at NYU Langone Health have identified the CK1 protein as a key player in cancer cell development. Inhibiting this enzyme may provide a new approach to treating cancer cells, particularly those with malfunctioning mTOR signaling pathways.
Researchers identify hyperactive c-Met protein as key player in ADPKD cyst growth, leading to potential therapeutic target. Pharmacological inhibition of c-Met decreases mTOR activity and blocks cyst formation in mouse model.
Researchers found that transforming growth factor-β1 contributes to kidney disease by inducing fibrosis and nephron degeneration. Meanwhile, a new diagnostic criteria for T-cell lymphoma was discovered using mast cells and Th17 cells. Additionally, a novel peptide ASARM may implicate in impaired dentin mineralization in rickets.
Researchers link PMSE syndrome to mTOR pathway, a complex network implicated in common neurological disorders with autism-like symptoms. The study reveals clues about TSC, a relatively common disorder, and its connection to PMSE and other neurological conditions.
Researchers at Burnham Institute for Medical Research discovered that the REDD1 protein is degraded under hypoxic conditions, enabling cells to rapidly restore mTOR signaling. This regulation mechanism plays a crucial role in cellular stress response and may be linked to tumor growth in cancer.
Scientists at the University of California, San Francisco, have created a new drug that blocks cancer's main source of growth and has proven effective in mice. The drug succeeds where similar compounds fail by blocking both mTOR signal pathways, making it a major advance over existing rapamycin-based drugs.